New York, Jan 18, 2026, 16:14 EST — The market has closed.
- Shares of Thermo Fisher dropped 0.95% Friday, closing at $618.72.
- U.S. markets remain closed Monday, extending the break before trading resumes.
- Thermo Fisher plans to release its results on Jan. 29, marking the next major catalyst on the calendar.
Thermo Fisher Scientific Inc closed Friday down 0.95% at $618.72, following a weak session for many life-sciences stocks as the broader market slipped.
Thermo Fisher’s next major milestone comes Jan. 29, when it plans to report Q4 and full-year 2025 results before the market opens, followed by a conference call at 8:30 a.m. ET.
The calendar now shows a holiday pause ahead. U.S. stock markets will shut down Monday in observance of Martin Luther King Jr. Day, so trading resumes Tuesday.
Investors are parsing the signals from Thermo Fisher this week on demand and policy shifts. CEO Marc Casper said the company’s pharma services division has secured several contracts linked to firms moving drug production back to the U.S., a trend he tied to tariff discussions. He also pointed to a brighter outlook in biotech funding. Evercore ISI analyst Vijay Kumar called the message “constructive,” though he remained cautious on forecasts for 2026. Reuters
Another leadership change is underway. In an 8-K filing with the U.S. Securities and Exchange Commission, Thermo Fisher announced that Chief Operating Officer Michel Lagarde will exit on March 31, while Executive Vice President Frederick Lowery is set to leave on Feb. 28. The company also detailed a March 1 shake-up: Casper is stepping in as chairman and CEO, Gianluca Pettiti moves up to president and COO, and Michael Shafer’s responsibilities will grow with a direct report line to the CEO.
Thermo Fisher is pushing to keep its instrument division front and center in the automation space. On Jan. 12, the company announced a strategic collaboration with Nvidia, focusing on harnessing AI to boost lab performance and enhance scientific instruments.
The stock’s next move probably depends more on the numbers than the news. Traders want clear signals that order trends are solid and that biotech and pharma clients are maintaining steady spending. A weak forecast could easily overshadow a decent quarter and drag down the entire tools group.
Monday’s closure means the calendar takes center stage for now: investors are eyeing Thermo Fisher’s Jan. 29 report and conference call as the next major catalyst.
